Yaohai Bio-Pharma operates a cutting-edge microbial CRDMO platform built on E. coli and yeast expression systems. In addition, we offer one-stop microbial cell banking solutions covering strain development, primary cell bank (PCB), master cell bank (MCB), and working cell bank (WCB) construction, strain preservation, genetic and storage stability studies, and full quality testing with regulatory support. As a result, clients can efficiently advance their biologics programs from gene to GMP-compliant cell banks while meeting global regulatory standards. All MCB and WCB services are carried out in independent GMP-certified facilities to ensure biosafety, contamination control, and product integrity.
E. coli Expression System
E. coli remains one of the most widely used and cost-effective systems for recombinant protein production. It provides rapid cell growth, high yield, good stability, and strong contamination resistance. Therefore, it is ideal for non-glycosylated proteins such as plasmid-based products, peptide hormones, and cytokines.
Yeast Expression System
Yeast combines prokaryotic simplicity with eukaryotic functionality. It enables fast growth, high-density fermentation, and efficient secretion expression, which reduces downstream purification costs. Furthermore, its glycosylation capability makes it suitable for enzymes, hormones, and therapeutic proteins.
End-to-End Microbial Cell Banking Solutions
Our services include:
Strain design, construction, and optimization
Clone screening and characterization
PCB, MCB, and WCB establishment in GMP-certified facilities
Genetic and storage stability studies
Comprehensive quality control and documentation support
In addition, we offer multiple strain preservation methods, internal regulatory support, external GMP audit access, and transparent project communication. Average microbial cell bank construction timelines are 4–6 months (without long-term stability studies).
About Yaohai Bio-Pharma
Yaohai Bio-Pharma is a CRDMO with extensive expertise in microbial expression systems. We focus on recombinant proteins, nucleic acid drugs, nanobodies, plasmid DNA, and innovative vaccines. From R&D to commercial manufacturing, we offer full-lifecycle solutions. Our mission is to build an open, integrated CRO/CDMO/MAH platform that supports global partners from discovery to market.
